Across TCGA pan-cancer cohorts, SH2D1A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SH2D1A data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SH2D1A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SH2D1A expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where SH2D1A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.859	0.631	<.001	46	view →
LUAD	DFS	Median	All	0.793	0.475	<.001	23	view →
CCRCC	OS	Median	II,III,IV	0.917	0.579	<.001	17	view →
HNSC	DFS	Tertile	II,III,IV	0.686	0.883	.025	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SH2D1A tumor-vs-normal RNA expression · all SH2D1A data types